Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 304

[22] Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, et al. DNA inoculation
induces neutralizing immune responses against human immunodeficiency virus type 1 in
mice and nonhuman primates. DNA Cell Biol 1993;12:799-805.
[23] Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous
secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol
Genet 1993;2:1847-51.
[24] Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA:
mechanism of CTL priming. J Exp Med 1996;184:1555-60.
[25] Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone
marrow-derived cells in CTL induction following plasmid DNA immunization at differ-
ent sites. J Immunol 1997;159:11-14.
[26] Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by
dendritic cells after immunization with DNA encoding a major histocompatibility com-
plex class II-restricted viral epitope. J Exp Med 1997;186:1481-6.
[27] Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macro-
phages for presentation by class I MHC molecules. J Immunol 1994;153:4925-33.
[28] Falo Jr LD, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into
the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995;1:
649-53.
[29] Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I-
restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: anti-
gen presentation by non-muscle cells. Immunology 1996;89:59-67.
[30] Fu TM, Ulmer JB, Caulfield NJ, Deck RR, Friedman A, Wang S, et al. Priming of cyto-
toxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting
cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-71.
[31] Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination:
transfection and activation of dendritic cells as key events for immunity. J Exp Med
1999;189:169-78.
[32] Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-
term cellular immunity. Curr Opin Immunol 2000;12:442-7.
[33] Stevenson FK. DNA vaccines against cancer: from genes to therapy. Ann Oncol
1999;10:1413-18.
[34] MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, et al. First human trial of
a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection:
safety and host response. J Infect Dis 1998;178:92-100.
[35] Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, et al. Cellular
cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet
1998;351:1320-5.
[36] MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune
responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine
in HIV-infected recipients: follow-up data [Letter]. J Infect Dis 2000;181:406.
[37] Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of antigen-
specific CD8  T cells, T helper cells, and protective levels of antibody in humans by
particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19:
764-78.
[38] Kouraklis G. Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 2000;
45:1045-52.
[39] American Cancer SocietyCancer facts and figures 2009. Atlanta, GA: American Cancer
Society; 2009.